CAESAREA, Israel: DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has successfully sold the first Lightning-enabled version of the acclaimed Dario Blood Glucose Monitoring System in the United Kingdom, according to schedule.
The Lightning-enabled device ensures that consumers will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8 and iPhone X.
Apple iOS has just over 50% market share in the U.K. With additional potential users, DarioHealth believes that it will be able to quickly increase U.K.-driven revenues and achieve greater market penetration.
This news comes shortly after the company's recent announcement of receiving the Therapeutic Goods Administration (TGA) Mark in the Australian market for the same Lightning-enabled device. Sales of the device are expected to begin in Australia mid-January. DarioHealth expects to hear from the U.S. Food and Drug Administration (F.D.A.) about necessary clearance over the next few months.
"As the digital world continuously evolves, we are committed to offering people with diabetes the most up-to-date technology to manage the disease," said Erez Raphael, Chairman and CEO of DarioHealth. "We are excited to begin sales of our Lightning-enabled device in the U.K. and we look forward to doing the same in Australia and the U.S."
